Cart
sales@molnova.com
SGI-1776
CAS No. 1025065-69-3
SGI-1776( SGI 1776 | SGI1776 )
Catalog No. M10114 CAS No. 1025065-69-3
SGI-1776 is a potent, selective, orally active Pim kinase inhibitor with IC50 of 7, 363 and 69 nM for Pim1, Pim2 and Pim3, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 158 | In Stock |
|
| 25MG | 288 | In Stock |
|
| 50MG | 415 | In Stock |
|
| 100MG | 532 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSGI-1776
-
NoteResearch use only, not for human use.
-
Brief DescriptionSGI-1776 is a potent, selective, orally active Pim kinase inhibitor with IC50 of 7, 363 and 69 nM for Pim1, Pim2 and Pim3, respectively.
-
DescriptionSGI-1776 is a potent, selective, orally active Pim kinase inhibitor with IC50 of 7, 363 and 69 nM for Pim1, Pim2 and Pim3, respectively; exhibits promising selectivity against a panel of >300 kinases, shows inhibitory activity against two other kinases: Flt-3 (IC50=44 nM) and Haspin (IC50=34 nM); reduces cell viability of androgen-independent prostate cancer cell lines with IC50 of 2-4 uM, causes cell cycle arrest and caspase-dependent apoptosis in prostate cancer cells, marginally sensitizes prostate cancer cells to taxane-based therapeutics by inhibiting MDR1 activity and inducing apoptosis; shows efficacy in xenograft model bearing MV-4-11 tumors.Prostate Cancer Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsSGI 1776 | SGI1776
-
PathwayJAK/STAT Signaling
-
TargetPim
-
RecptorFLT3|Pim1|Pim2|Pim3
-
Research AreaCancer
-
IndicationProstate Cancer
Chemical Information
-
CAS Number1025065-69-3
-
Formula Weight405.42
-
Molecular FormulaC20H22F3N5O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESFC(F)(F)OC1=CC=C(C2=CN=C3C=CC(NCC4CCN(C)CC4)=NN32)C=C1
-
Chemical NameImidazo[1,2-b]pyridazin-6-amine, N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen LS, et al. Blood. 2009 Nov 5;114(19):4150-7.
2. Chen LS, et al. Blood. 2011 Jul 21;118(3):693-702.
3. Chang M, et al. Mol Cancer Ther. 2010 Sep;9(9):2478-87.
4. Mumenthaler SM, et al. Mol Cancer Ther. 2009 Oct;8(10):2882-93.
molnova catalog
related products
-
R8-T198wt
Cell-permeable peptide inhibitor of Pim-1 kinase, derived from p27Kip1. Inhibits Pim-1 phosphorylation of p27Kip1 and Bad; induces cell cycle arrest (at G1) and apoptosis in DU145 prostate cancer cells. Also inhibits Pim-1-dependent growth of DU145 cells in vitro and in vivo. Displays no effect on the growth of normal prostate epithelial RPWE-1 cells at concentrations of 10 and 20 μM.
-
YLT-11
YLT-11 (PLK4 inhibitor YLT11) is a novel potent, selective, ATP-competitive PLK4 inhibitor with IC50 of 22 nM, Kd of 5.2 nM.
-
Pim inhibitor 28
Pim inhibitor 28 is a potent, selective inhibitor of Pim1/2 with IC50 of 0.05 nM.
